Table 2.
Characteristics of youth accessing outpatient HIV care and treatment services in Kisumu, Kenya, by clinic type, July 2007–September 2010.
| Characteristic | Total (n = 924) | Youth-specific clinic (n = 584) | Family-oriented clinic (n = 340) | p-value |
|---|---|---|---|---|
| Median age (years) | 20 (IQR 19–21) | 19 (IQR 18–20) | <0.001 | |
| Gender (female) | 732 (79%) | 418 (72%) | 314 (92%) | <0.001 |
| Became pregnant during study | 209 (23%) | 64 (11%) | 145 (43%) | <0.001 |
| Marital statusa | ||||
| Married/partnered | 295 (32%) | 129 (22%) | 166 (49%) | <0.001 |
| Not married/partnered | 471 (51%) | 363 (62%) | 108 (32%) | |
| Currently working/employed | 55 (6%) | 13 (2%) | 42 (12%) | <0.001 |
| Median CD4 count (cells/mm3) | 446 (IQR 275–675) | 401 (IQR 217–576) | 0.001 | |
| CD4 cell count (cells/mm3)b | ||||
| <250 | 219 (24%) | 159 (27%) | 60 (18%) | 0.014 |
| 250–349 | 96 (10%) | 56 (9%) | 40 (12%) | |
| ≥350 | 480 (52%) | 300 (52%) | 179 (52%) | |
| WHO clinical disease stagec | ||||
| Stage I/II | 737 (80%) | 474 (81%) | 263 (77%) | 0.098 |
| Stage III/IV | 172 (19%) | 99 (17%) | 73 (21%) | |
| Highest education level attainedd | ||||
| None | 14 (2%) | 10 (2%) | 4 (1%) | 0.002 |
| Primary | 532 (58%) | 309 (53%) | 223 (65%) | |
| Secondary | 250 (27%) | 167 (29%) | 83 (24%) | |
| Tertiary | 38 (4%) | 32 (5%) | 6 (2%) | |
| Disclosed HIV infection status | 591 (64%) | 346 (59%) | 245 (75%) | 0.001 |
| Ever initiated on ART | 364 (39%) | 204 (35%) | 160 (47%) | <0.001 |
| Discontinued from care | 60 (7%) | 25 (4%) | 35 (10%) | |
| Deceased | 9 (1%) | 5 (1%) | 4 (1%) | 0.27 |
| Transferred out | 48 (5%) | 20 (3%) | 28 (8%) | |
| Withdrew from care | 3 (0.3%) | 0 | 3 (1%) | |
| Lost to follow-up | 529 (57%) | 354 (61%) | 175 (51%) | 0.007 |
a
Marital status was missing for 158 patients (17%).
b
CD4 cell count was missing for 129 patients (14%).
c
WHO staging was missing for 15 patients (2%).
d
Educational status was missing for 90 patients (10%).
e
Disclosure status was missing for 65 patients (7%).